Myriad Genetics, Inc. (MYGN) is an interesting player in the Services space, with a focus on Research Services. The stock has been active on the tape, currently trading at $29.52, up from yesterdays close by 0.92%. Given the stocks recent action, it seemed like a good time to take a closer look at the companys recent data.

Fundamental Analysis

This company has been competing with others in the Services space and offers its own combination of interesting factors Myriad Genetics, Inc. (MYGN) currently trades with a market capitalization of $2.03 Billion. That value represents a market adjusting for revenues that have been growing by 7.56 % on a quarterly year/year basis as of the companys last quarterly report.

The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For MYGN, the company currently has $102.4 Million of cash on the books. You can get a sense of how sustainable that is by a levered free cash flow of $100.1 Million over the past twelve months. Generally speaking, earnings are expected to grow in coming quarters. Analysts are forecasting earnings of $0.21 on a per share basis this quarter. Perhaps, that suggests something about why 96.67% of the outstanding share supply is held by institutional investors.

Technical Analysis

Sometimes, we can understand most about a stock by simply looking at how it has been trading. Looking at the stocks movement on the chart, Myriad Genetics, Inc. recorded a 52-week high of $29.52. It is now trading 0% off that level. The stock is trading $25.76 its 50-day moving average by -3.76%. The stock carved out a 52-week low down at $15.15.

In recent action, Myriad Genetics, Inc. (MYGN) has made a move of +25.83% over the past month, which has come on weak relative transaction volume. Over the trailing year, the stock is outperforming the S&P 500 by 27.56, and its gotten there by action that has been less volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 31.15% with $67.78 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of MYGN.

Read the original post:
Drilling Down Into Myriad Genetics, Inc. (MYGN) - StockNewsJournal